Chronic Kidney Disease (CKD) Guidelines

1. Vaidya SR, Aeddula NR. Chronic Renal Failure. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007 Oct. 18(10):2758-65. [QxMD MEDLINE Link].

3. Centers for Disease Control and Prevention. Deaths and Mortality. Available at http://www.cdc.gov/nchs/fastats/deaths.htm. September 6, 2022; Accessed: February 10, 2023.

4. [Guideline] Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 Jul 15. 139(2):137-47. [QxMD MEDLINE Link].

5. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013. 3:1-150. [Full Text].

6. Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. Pediatr Nephrol. 2014 Feb. 29 (2):193-202. [QxMD MEDLINE Link].

7. Lameire N, Van Biesen W. The initiation of renal-replacement therapy--just-in-time delivery. N Engl J Med. 2010 Aug 12. 363(7):678-80. [QxMD MEDLINE Link].

8. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011 Nov. 6(11):2567-72. [QxMD MEDLINE Link].

9. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2009 Apr. 53(4):596-605. [QxMD MEDLINE Link]. [Full Text].

10. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012 Dec 12. 308(22):2349-60. [QxMD MEDLINE Link]. [Full Text].

11. de Boer IH. Chronic kidney disease—a challenge for all ages. JAMA. 2012 Dec 12. 308(22):2401-2. [QxMD MEDLINE Link]. [Full Text].

12. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-Based Risk Assessment of APOL1 on Renal Disease. J Am Soc Nephrol. 2011 Nov. 22(11):2098-105. [QxMD MEDLINE Link].

13. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15. 305(23):2432-9. [QxMD MEDLINE Link]. [Full Text].

14. Ellis JW, Chen MH, Foster MC, Liu CT, Larson MG, de Boer I, et al. Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet. 2012 Jul 15. 21(14):3293-8. [QxMD MEDLINE Link]. [Full Text].

15. Pattaro C, Köttgen A, Teumer A, et al. Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet. 2012. 8(3):e1002584. [QxMD MEDLINE Link]. [Full Text].

16. Nordfors L, Luttropp K, Carrero JJ, Witasp A, Stenvinkel P, Lindholm B, et al. Genetic studies in chronic kidney disease: basic concepts. J Nephrol. 2012 Mar-Apr. 25(2):141-9. [QxMD MEDLINE Link].

17. Su SL, Lu KC, Lin YF, Hsu YJ, Lee PY, Yang HY, et al. Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. J Renin Angiotensin Aldosterone Syst. 2012 Mar. 13(1):148-54. [QxMD MEDLINE Link].

18. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014. 9(1):e84943. [QxMD MEDLINE Link]. [Full Text].

19. Gallo Marin B, Aghagoli G, Hu SL, Massoud CM, Robinson-Bostom L. Calciphylaxis and Kidney Disease: A Review. Am J Kidney Dis. 2023 Feb. 81 (2):232-239. [QxMD MEDLINE Link]. [Full Text].

20. Chronic Kidney Disease in the United States, 2021. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/kidneydisease/publications-resources/CKD-national-facts.html. Jully 12, 2022; Accessed: February 10, 2023.

21. Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. Available at https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease#urologic. September 2021; Accessed: February 10, 2023.

22. CKD in the General Population. United States Renal Data System. Available at https://adr.usrds.org/2020/chronic-kidney-disease/1-ckd-in-the-general-population. 2022 Annual Report; Accessed: February 10, 2023.

23. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29. 395 (10225):709-733. [QxMD MEDLINE Link]. [Full Text].

24. Kampmann JD, Heaf JG, Mogensen CB, Mickley H, Wolff DL, Brandt F. Prevalence and incidence of chronic kidney disease stage 3-5 - results from KidDiCo. BMC Nephrol. 2023 Jan 19. 24 (1):17. [QxMD MEDLINE Link]. [Full Text].

25. Feng T, Xu Y, Zheng J, Wang X, Li Y, Wang Y, et al. Prevalence of and risk factors for chronic kidney disease in ten metropolitan areas of China: a cross-sectional study using three kidney damage markers. Ren Fail. 2023 Dec. 45 (1):2170243. [QxMD MEDLINE Link]. [Full Text].

26. Vart P, Powe NR, McCulloch CE, Saran R, Gillespie BW, Saydah S, et al. National Trends in the Prevalence of Chronic Kidney Disease Among Racial/Ethnic and Socioeconomic Status Groups, 1988-2016. JAMA Netw Open. 2020 Jul 1. 3 (7):e207932. [QxMD MEDLINE Link]. [Full Text].

27. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. 2009 Jul. 122(7):672-8. [QxMD MEDLINE Link]. [Full Text].

28. Schold JD, Srinivas TR, Braun WE, et al. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Clin Transplant. 2011 Sep. 25(5):721-30. [QxMD MEDLINE Link].

29. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, et al. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. Kidney Int. 2011 Dec. 80(12):1339-43. [QxMD MEDLINE Link].

30. Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol. 2009 Apr. 4(4):812-9. [QxMD MEDLINE Link]. [Full Text].

31. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005 Sep. 68(3):914-24. [QxMD MEDLINE Link].

32. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011 Apr 20. 305(15):1553-9. [QxMD MEDLINE Link].

33. United States Renal Data System. Incidence, Prevalence,Patient Characteristics, and Treatment Modalities. 2018 Annual Data Report. Volume 2: ESRD in the United States: [Full Text].

34. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2. 341(23):1725-30. [QxMD MEDLINE Link].

35. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, et al. Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol. 2013 Feb. 24(3):498-505. [QxMD MEDLINE Link]. [Full Text].

36. McNamara D. More frequent dialysis increases risk for complications. February 13, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/779265. Accessed: August 29, 2013.

37. Sens F, Schott-Pethelaz AM, Labeeuw M, Colin C, Villar E. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. Kidney Int. 2011 Nov. 80(9):970-7. [QxMD MEDLINE Link].

38. Wald R, Yan AT, Perl J, et al. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrol. 2012 Jan 19. 13(1):3. [QxMD MEDLINE Link].

39. Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011 Feb. 79(3):356-62. [QxMD MEDLINE Link].

40. Navaneethan SD, Schold JD, Arrigain S, et al. Low 25-Hydroxyvitamin D Levels and Mortality in Non-Dialysis-Dependent CKD. Am J Kidney Dis. 2011 Oct. 58(4):536-43. [QxMD MEDLINE Link]. [Full Text].

41. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis. 2012 Oct. 60(4):567-75. [QxMD MEDLINE Link]. [Full Text].

42. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis. 2011 Oct. 58(4):536-43. [QxMD MEDLINE Link]. [Full Text].

43. Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Validation of depression screening scales in patients with CKD. Am J Kidney Dis. 2009 Sep. 54(3):433-9. [QxMD MEDLINE Link].

44. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5. 367(1):20-9. [QxMD MEDLINE Link].

45. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem. 2002 May. 48(5):699-707. [QxMD MEDLINE Link].

46. Lemoine S, Panaye M, Pelletier C, Bon C, Juillard L, Dubourg L, et al. Cystatin C-Creatinine Based Glomerular Filtration Rate Equation in Obese Chronic Kidney Disease Patients: Impact of Deindexation and Gender. Am J Nephrol. 2016 Jul 12. 44 (1):63-70. [QxMD MEDLINE Link].

47. Barclay L. ACP Guidelines: Do Not Screen Asymptomatic Adults for CKD. Medscape Medical News. Oct 21 2013. January 8, 2018. [Full Text].

48. Barclay L. CKD: ASN Recommends Screening, Rejects ACP Statement. Medscape Medical News. Oct 23 2013. January 8, 2018. [Full Text].

49. [Guideline] Qaseem A, Hopkins RH, Sweet DE, et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013 Oct 22. [QxMD MEDLINE Link].

50. Galbraith LE, Ronksley PE, Barnieh LJ, Kappel J, Manns BJ, Samuel SM, et al. The See Kidney Disease Targeted Screening Program for CKD. Clin J Am Soc Nephrol. 2016 Jun 6. 11 (6):964-72. [QxMD MEDLINE Link].

51. [Guideline] National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. 2002; Accessed: February 28, 2018.

52. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16. 130(6):461-70. [QxMD MEDLINE Link].

53. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010 Sep. 56(3):486-95. [QxMD MEDLINE Link]. [Full Text].

54. Silveiro SP, Araújo GN, Ferreira MN, Souza FD, Yamaguchi HM, Camargo EG. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation pronouncedly underestimates glomerular filtration rate in type 2 diabetes. Diabetes Care. 2011 Nov. 34(11):2353-5. [QxMD MEDLINE Link]. [Full Text].

55. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar. 20(3):629-37. [QxMD MEDLINE Link]. [Full Text].

56. [Guideline] Nesrallah GE, Mustafa RA, Clark WF, Bass A, Barnieh L, Hemmelgarn BR, et al. Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. CMAJ. 2014 Feb 4. 186(2):112-7. [QxMD MEDLINE Link]. [Full Text].

57. Harrison L. Canada Guidelines Call for Kidney Dialysis Delay. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/820114. Accessed: February 10, 2014.

58. [Guideline] ElSayed NA, et al, on behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1. 46 (Suppl 1):S191-S202. [QxMD MEDLINE Link]. [Full Text].

59. Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2013 Dec 16. [QxMD MEDLINE Link].

60. Park M, Hsu CY. An ACE in the hole for patients with advanced chronic kidney disease?. JAMA Intern Med. 2013 Dec 16. [QxMD MEDLINE Link].

61. O'Hare AM, Hotchkiss JR, Kurella Tamura M, et al. Interpreting Treatment Effects From Clinical Trials in the Context of Real-World Risk Information: End-Stage Renal Disease Prevention in Older Adults. JAMA Intern Med. 2014 Jan 13. [QxMD MEDLINE Link].

62. Perkovic V, et al; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13. 380 (24):2295-2306. [QxMD MEDLINE Link]. [Full Text].

63. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020 Jul. 8 (7):582-593. [QxMD MEDLINE Link].

64. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8. 383 (15):1436-1446. [QxMD MEDLINE Link]. [Full Text].

65. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug. 7 (8):606-617. [QxMD MEDLINE Link].

66. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12. 388 (2):117-127. [QxMD MEDLINE Link].

67. Bakris GL, et al; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. October 23, 2020. [Full Text].

68. Zoler ML. Novel Drug Slows Progression of Diabetic Kidney Disease. Medscape Medical News. Available at https://www.medscape.com/viewarticle/939724. October 23, 2020; Accessed: October 26, 2020.

69. [Guideline] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15. 71 (19):2199-2269. [QxMD MEDLINE Link]. [Full Text].

70. [Guideline] Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar. 99 (3):559-569. [QxMD MEDLINE Link]. [Full Text].

71. Peralta CA, Norris KC, Li S, et al. Blood Pressure Components and End-stage Renal Disease in Persons With Chronic Kidney Disease: The Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 9. 172(1):41-47. [QxMD MEDLINE Link].

72. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. J Am Soc Nephrol. 2011 Dec. 22(12):2313-21. [QxMD MEDLINE Link].

73. Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996 Dec. 7(12):2616-26. [QxMD MEDLINE Link].

74. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998 Jun. 31(6):954-61. [QxMD MEDLINE Link].

75. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009 Oct. 54(4):647-52. [QxMD MEDLINE Link].

76. Douglas D. Vitamin D Curbs Albuminuria in Kidney Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/810806. Accessed: September 16, 2013.

77. Molina P, Górriz JL, Molina MD, Peris A, Beltrán S, Kanter J, et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study. Nephrol Dial Transplant. 2013 Aug 24. [QxMD MEDLINE Link].

78. Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal Anti-Inflammatory Drug Use Among Persons With Chronic Kidney Disease in the United States. Ann Fam Med. 2011 September-October. 9(5):423-430. [QxMD MEDLINE Link]. [Full Text].

79. Brown T. Potentially Unsafe Prescribing Common in Patients With CKD. Medscape Medical News. Available at https://www.medscape.com/viewarticle/893606. March 8, 218; Accessed: March 9, 2018.

80. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int. 2011 Sep. 80(5):516-23. [QxMD MEDLINE Link].

81. Busko M. L-thyroxine dampens renal function decline in CKD with SCH. June 19, 2013. Medscape Medical News [serial online]. Available at http://www.medscape.com/viewarticle/806543. Accessed: June 25, 2013.

82. Shin DH, Lee MJ, Lee HS, Oh HJ, Ko KI, Kim CH, et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid. 2013 Jun. 23(6):654-61. [QxMD MEDLINE Link]. [Full Text].

83. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney Disease: A Population-Based Cohort Study. Arch Intern Med. 2011 Nov 28. 171(21):1920-1927. [QxMD MEDLINE Link].

84. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Jun. 69 (6):815-826. [QxMD MEDLINE Link]. [Full Text].

85. FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis. U.S. Food & Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis. February 8, 2023; Accessed: February 9, 2023.

86. Singh AK, Carroll K, Perkovic V, and the, ASCEND-D Study Group. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Dec 16. 385 (25):2325-2335. [QxMD MEDLINE Link]. [Full Text].

87. Singh AK, Carroll K, McMurray JJV, and the, ASCEND-ND Study Group. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 Dec 16. 385 (25):2313-2324. [QxMD MEDLINE Link]. [Full Text].

88. [Guideline] Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018 Feb 20. S1-130. [QxMD MEDLINE Link]. [Full Text].

89. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017 Dec. 70 (6):737-751. [QxMD MEDLINE Link].

90. [Guideline] Dasgupta I, Shroff R, Bennett-Jones D, McVeigh G, NICE Hyperphosphataemia Guideline Development Group. Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline. Nephron Clin Pract. 2013. 124 (1-2):1-9. [QxMD MEDLINE Link]. [Full Text].

91. Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharm J. 2016 Jul. 24 (4):494-505. [QxMD MEDLINE Link]. [Full Text].

92. Rizk R. Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go. BMC Nephrol. 2016 Jul 8. 17 (1):75. [QxMD MEDLINE Link]. [Full Text].

93. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug. 23(8):1407-15. [QxMD MEDLINE Link]. [Full Text].

94. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep. 20(9):2075-84. [QxMD MEDLINE Link]. [Full Text].

95. Harrison P. Sodium Bicarbonate Slows Chronic Kidney Disease Safely. Medscape Medical News. Available at https://www.medscape.com/viewarticle/914574. June 18, 2019; Accessed: July 19, 2019.

96. Barclay L. CKD: KDIGO Guidelines Recommend Wider Use of Statins. Medscape Medical News. Available at http://www.medscape.com/viewarticle/817504. Accessed: December 16, 2013.

97. [Guideline] Tonelli M, Wanner C. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2013 Dec 10. [QxMD MEDLINE Link].

98. Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2019 Jul 16. [QxMD MEDLINE Link].

99. Piccoli GB, Capizzi I, Vigotti FN, Leone F, D'Alessandro C, Giuffrida D, et al. Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines?. BMC Nephrol. 2016 Jul 8. 17 (1):76. [QxMD MEDLINE Link]. [Full Text].

100. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010 Dec 8. CD006763. [QxMD MEDLINE Link].

101. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011 Jul 26. 343:d4366. [QxMD MEDLINE Link]. [Full Text].

102. Vegter S, Perna A, Postma MJ, et al. Sodium Intake, ACE Inhibition, and Progression to ESRD. J Am Soc Nephrol. 2012 Jan. 23(1):165-73. [QxMD MEDLINE Link].

103. Romanowski A. Diets for Patients With CKD: What's New, What's Best?. Medscape Medical News. Available at https://www.medscape.com/viewarticle/910884. March 27, 2019; Accessed: May 1, 2019.

104. Clegg DJ, Hill Gallant KM. Plant-Based Diets in CKD. Clin J Am Soc Nephrol. 2019 Jan 7. 14 (1):141-143. [QxMD MEDLINE Link]. [Full Text].

105. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int. 2012 Jan. 81(1):86-93. [QxMD MEDLINE Link].

106. Mallamaci F, Pisano A, Tripepi G. Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. Nephrol Dial Transplant. 2020 Mar 1. 35 (Suppl 2):ii18-ii22. [QxMD MEDLINE Link]. [Full Text].

107. Barcellos FC, Santos IS, Umpierre D, Bohlke M, Hallal PC. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J. 2015 Dec. 8 (6):753-65. [QxMD MEDLINE Link].

108. Sakaguchi Y, Shoji T, Kawabata H, Niihata K, Suzuki A, Kaneko T, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol. 2011 May. 6(5):995-1000. [QxMD MEDLINE Link]. [Full Text].

109. [Guideline] Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May. 63 (5):713-35. [QxMD MEDLINE Link]. [Full Text].

Pradeep Arora, MD Assistant Professor of Medicine, University of Buffalo State University of New York School of Medicine and Biomedical Sciences; Attending Nephrologist, Veterans Affairs Western New York Healthcare System

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Laura Lyngby Mulloy, DO, FACP Professor of Medicine, Chief, Section of Nephrology, Hypertension, and Transplantation Medicine, Glover/Mealing Eminent Scholar Chair in Immunology, Medical College of Georgia

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mauro Verrelli, MD, FRCP(C), FACP Assistant Professor, Department of Medicine, Section of Nephrology, University of Manitoba, Canada

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article